Why Are Psychedelics More Regulated Than Marijuana? A Deep Dive into Contradictions and Perceptions

The landscape of drug policy in Canada transformed with the legalization of cannabis, a move that reflects a broader global trend towards acceptance of this once-stigmatized substance. Despite this progress, psychedelics, which have been increasingly studied and recognized for their ability to treat mental health concerns, continue to face strict regulations, often being categorized alongside the most dangerous narcotics. This situation raises an important question: why are psychedelics more regulated than marijuana, especially when marijuana is considered less potent and less promising in therapeutic applications?

One major factor is the historical baggage that comes with psychedelics. The social unrest of the 1960s, often associated with recreational use of these substances, has contributed to a narrative that paints psychedelics as dangerous and unpredictable. This view, largely politically driven, has led to their classification as Schedule I drugs, which denotes substances with a high potential for abuse and no recognized medical use — a classification that stands at odds with the growing body of scientific research supporting their therapeutic benefits.

Another significant aspect is the perceived “uncontrollability” of the psychedelic experience. Unlike marijuana, whose effects are typically milder and shorter-lived, psychedelics can provoke deep, introspective experiences that last for several hours. This unpredictability, often exaggerated by sensational media portrayals, adds to the fear and stringent regulations surrounding these substances.

However, perspectives are changing. ATMA’s Psychedelic-Assisted Therapy Training programs are paving the way for a more educated and ethical approach to administering these substances in therapeutic settings. Such programs focus on responsible use and harm reduction, playing an important role in transforming the public narrative from one of fear to one of healing potential.

The efficacy of Psychedelic-Assisted Therapy in treating conditions like PTSD, depression, and addiction is reevaluating long-standing assumptions about these substances. ATMA is contributing to advancing the research, currently running Phase II clinical trials for psilocybin. As more scientific evidence emerges showing the benefits of psychedelics under controlled conditions, it becomes increasingly difficult to justify their strict regulation.

This stark regulatory contrast with marijuana, especially in a country where cannabis is legal, highlights a significant discrepancy. While the legalization of cannabis has been partly driven by economic interests, the profound therapeutic potentials of psychedelics remain largely untapped due to their restrictive regulatory status. This situation underscores the need for policy reforms based on evidence and public health considerations rather than outdated fears and political agendas.

In conclusion, the stricter regulation of psychedelics compared to marijuana is a complex issue, deeply rooted in historical stigma, perceived risks, and political influences. However, initiatives like ATMA’s training courses, the ATMA CENA clinics in Calgary and Edmonton, and the growing evidence of therapeutic benefits are challenging these old perceptions. Moving forward with a science-informed, compassionate approach could lead to a future where the full therapeutic potential of psychedelics is acknowledged and utilized, free from the constraints of unwarranted fear and outdated regulations.

William Jace is the author of this Article. To know more about ATMA Cena please visit the website